Facetten
Zugriff
Einrichtung
Medientyp
- Text 17
Karte
Erscheinungsjahr
Autor/in
- Blauvelt, Andrew
- Reich, Kristian 7
- Augustin, Matthias 5
- Langley, Richard G 5
- Papp, Kim A 4
- alle zeigen
Sprache
- Englisch 17
17 Einträge gefunden
-
Long-term 2-year safety and efficacy of tralokinumab in adults with moderate-to-severe atopic dermatitis: Interim analysis of the ECZTEND open-label extension trial
- Blauvelt, Andrew
- Langley, Richard G
- Lacour, Jean-Philippe
- Toth, Darryl
- Laquer, Vivian
- Beissert, Stefan
- Wollenberg, Andreas
-
Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial
- Reich, Kristian
- Thyssen, Jacob P
- Blauvelt, Andrew
- Eyerich, Kilian
- Soong, Weily
- Rice, Zakiya P
- Hong, H Chih-Ho
-
Efficacy of guselkumab versus secukinumab in subpopulations of patients with moderate-to-severe plaque psoriasis: results from the ECLIPSE study
- Blauvelt, Andrew
- Armstrong, April W
- Langley, Richard G
- Gebauer, Kurt
- Thaçi, Diamant
- Bagel, Jerry
- Guenther, Lyn C
-
Efficacy and safety of mirikizumab in psoriasis: results from a 52-week, double-blind, placebo-controlled, randomized withdrawal, phase III trial (OASIS-1)
- Blauvelt, Andrew
- Kimball, Alexa B
- Augustin, Matthias
- Okubo, Yukari
- Witte, Michael M
- Capriles, Claudia Rodriguez
- Sontag, Angelina
-
Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial
- Gordon, Kenneth B
- Foley, Peter
- Krueger, James G
- Pinter, Andreas
- Reich, Kristian
- Vender, Ronald
- Vanvoorden, Veerle
-
Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial
- Reich, Kristian
- Papp, Kim A
- Blauvelt, Andrew
- Langley, Richard G
- Armstrong, April
- Warren, Richard B
- Gordon, Kenneth B
-
Differential Changes in Inflammatory Mononuclear Phagocyte and T-Cell Profiles within Psoriatic Skin during Treatment with Guselkumab vs. Secukinumab
- Mehta, Heena
- Mashiko, Shunya
- Angsana, Julianty
- Rubio, Manuel
- Hsieh, Ya-Ching M
- Maari, Catherine
- Reich, Kristian
-
Bimekizumab versus Adalimumab in Plaque Psoriasis
- Warren, Richard B
- Blauvelt, Andrew
- Bagel, Jerry
- Papp, Kim A
- Yamauchi, Paul
- Armstrong, April
- Langley, Richard G
-
Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study
- Deleuran, Mette
- Thaçi, Diamant
- Beck, Lisa A
- de Bruin-Weller, Marjolein
- Blauvelt, Andrew
- Forman, Seth
- Bissonnette, Robert
-
Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years of Exposure
- Armstrong, April
- Paul, Carle
- Puig, Luis
- Boehncke, Wolf Henning
- Freeman, Michael
- Torii, Hideshi
- Papp, Kim
-
-
-
Certolizumab Pegol for the Treatment of Chronic Plaque Psoriasis: Results Through 48 Weeks of a Phase 3, Multicenter, Randomized, Double-Blinded, Etanercept- and Placebo-Controlled Study (CIMPACT)
- Lebwohl, Mark
- Blauvelt, Andrew
- Paul, Carle
- Sofen, Howard
- Węgłowska, Jolanta
- Piguet, Vincent
- Burge, Daniel
-
Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials
- Gordon, Kenneth B
- Strober, Bruce
- Lebwohl, Mark
- Augustin, Matthias
- Blauvelt, Andrew
- Poulin, Yves
- Papp, Kim A
-
Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders. A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3)
- Blauvelt, Andrew
- Papp, Kim A
- Griffiths, Christopher E M
- Puig, Luis
- Weisman, Jamie
- Dutronc, Yves
- Kerr, Lisa Farmer
-
Continuous Dosing Versus Interrupted Therapy with Ixekizumab: An Integrated Analysis of Two Phase 3 Trials in Psoriasis
2017 - Forschungsinformationssystem des UKE -